On pages 399 and 400 in the January 8, 2009, issue, there were 3 errors.
In Figure 3B, the label that reads “Raji-m2” for the third black bar in both graphs is incorrect. The label should read “Raji-m1.”
On page 400 under the heading “Effects of ASOs in Jeko-1 cells reveal that p21 is an essential target of the miR-17-92 polycistron during lymphomagenesis,” the fourth sentence is incorrect. TP53INP1 should not have appeared in the sentence. The correct sentence should read: “RQ-PCR analysis of CDKN1A expression in Jeko-1 cells treated with ASOs or SCOs revealed that although there was no significant difference between expression levels in cells treated with AS-19 or SC-19, cells treated with AS-17, with or without AS-20, showed greater expression than cells treated with the respective SCOs (Figure 5B).”
The legend for Figure 4 is incorrect. In the second sentence, reference to miR-17 expression and SUDHL4 cells is incorrect. The last sentence is missing the word “as.” The correct figure legend follows:
Figure 4. Jeko-1 cells show both miR-17\N92 overexpression and homozygous deletion of BIM. (A) Northern blot analysis of miR-19 and miR-20a expression in 4 B-cell lymphoma cell lines: lane 1 represents Jeko-1; lane 2, SP49; lane 3, SUDHL4; and lane 4, Raji. Fold changes in miR-19a and 20a expressions are shown below the gels and normalized to the level in Jeko-1 cells, which was assigned a value of 1.00. (B) Top panels: Southern blot analysis (SB) of the BIM locus carried out using genomic DNA, including BIM, from the 4 indicated cell lines. Bottom panels: Northern blot analysis (NB) of BIM, from the 4 indicated cell lines. A cDNA fragment of β-actin was used as a control.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal